Intercept Pharmaceuticals to Provide 2013 Update on Clinical Programs for
Obeticholic Acid on January 9
NEW YORK, Jan. 2, 2014 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc.
(Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused
on the development and commercialization of novel bile acid therapeutics to
treat chronic liver diseases, today announced that it will provide an update
on the progress of its clinical development programs after the NASDAQ Market
closes on January 9, 2014. This update will provide, among other items,
information on the completion of the double-blind phase of the POISE trial,
top line data from the OBADIAH and PESTO trials and 2014 anticipated
milestones. Intercept management will conduct a conference call and audio
webcast at 4:30 p.m. EDT on the same day.
Date: January 9, 2014
Time: 4:30 PM ET
Teleconference and webcast details will be available at:
http://ir.interceptpharma.com/. A replay of the call will be available on
Intercept's website approximately two hours after the completion of the call
and will be archived for two weeks.
Intercept is a biopharmaceutical company focused on the development and
commercialization of novel therapeutics to treat orphan and more prevalent
liver diseases utilizing its expertise in bile acid chemistry. The company's
lead product candidate, obeticholic acid (OCA), is a bile acid analog and
first-in-class agonist of the farnesoid X receptor (FXR). OCA is initially
being developed for the second line treatment of primary biliary cirrhosis
(PBC) in patients with an inadequate response to, or who are unable to
tolerate, ursodiol, the only approved therapy for this indication. OCA has
received orphan drug designation in both the United States and Europe for the
treatment of PBC. Intercept owns worldwide rights to OCA outside of Japan and
China, where it has out-licensed the product candidate to Dainippon Sumitomo
Pharma. For more information about Intercept, please visit the Company's
website at: www.interceptpharma.com.
CONTACT: Barbara Duncan
Press spacebar to pause and continue. Press esc to stop.